Aprea Therapeutics (APRE) Competitors $1.66 -0.04 (-2.35%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.70 +0.04 (+2.11%) As of 08/1/2025 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APRE vs. ITRM, AKTX, MAAQ, KPTI, SNYR, JATT, KZR, CLNN, OKUR, and RNTXShould you be buying Aprea Therapeutics stock or one of its competitors? The main competitors of Aprea Therapeutics include Iterum Therapeutics (ITRM), Akari Therapeutics (AKTX), Mana Capital Acquisition (MAAQ), Karyopharm Therapeutics (KPTI), Synergy CHC (SNYR), JATT Acquisition (JATT), Kezar Life Sciences (KZR), Clene (CLNN), OnKure Therapeutics (OKUR), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry. Aprea Therapeutics vs. Its Competitors Iterum Therapeutics Akari Therapeutics Mana Capital Acquisition Karyopharm Therapeutics Synergy CHC JATT Acquisition Kezar Life Sciences Clene OnKure Therapeutics Rein Therapeutics Iterum Therapeutics (NASDAQ:ITRM) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment. Which has more risk and volatility, ITRM or APRE? Iterum Therapeutics has a beta of 2.85, meaning that its stock price is 185% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Which has preferable valuation & earnings, ITRM or APRE? Aprea Therapeutics has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$24.77M-$0.99-0.74Aprea Therapeutics$1.50M6.12-$12.96M-$2.37-0.70 Is ITRM or APRE more profitable? Iterum Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -1,095.02%. Iterum Therapeutics' return on equity of 0.00% beat Aprea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -71.37% Aprea Therapeutics -1,095.02%-68.39%-55.74% Do analysts rate ITRM or APRE? Iterum Therapeutics currently has a consensus target price of $9.00, suggesting a potential upside of 1,129.51%. Aprea Therapeutics has a consensus target price of $15.50, suggesting a potential upside of 833.73%. Given Iterum Therapeutics' higher probable upside, analysts plainly believe Iterum Therapeutics is more favorable than Aprea Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aprea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of ITRM or APRE? 9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 9.2% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer ITRM or APRE? In the previous week, Iterum Therapeutics had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 2 mentions for Iterum Therapeutics and 0 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.00 beat Iterum Therapeutics' score of -0.50 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Iterum Therapeutics Negative Aprea Therapeutics Neutral SummaryAprea Therapeutics beats Iterum Therapeutics on 8 of the 14 factors compared between the two stocks. Get Aprea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APRE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRE vs. The Competition Export to ExcelMetricAprea TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.40M$2.99B$5.48B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.7017.7428.8623.83Price / Sales6.12178.75371.7266.14Price / CashN/A41.9535.4557.96Price / Book0.478.508.275.54Net Income-$12.96M-$55.06M$3.25B$259.28M7 Day Performance-12.17%-3.99%-3.73%-4.68%1 Month Performance-2.35%9.58%4.29%4.36%1 Year Performance-55.85%6.70%25.87%17.89% Aprea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APREAprea Therapeutics2.8263 of 5 stars$1.66-2.4%$15.50+833.7%-55.4%$9.40M$1.50M-0.707Gap UpITRMIterum Therapeutics1.5797 of 5 stars$0.87-5.0%$9.00+933.3%-37.7%$36.66MN/A-0.8810Upcoming EarningsShort Interest ↑Gap UpAKTXAkari Therapeutics2.6884 of 5 stars$1.14+0.4%$5.00+340.5%-73.1%$36.36MN/A0.009High Trading VolumeMAAQMana Capital AcquisitionN/A$4.30-6.9%N/A+875.0%$34.94MN/A0.001Gap DownKPTIKaryopharm Therapeutics3.4275 of 5 stars$4.02+4.4%$37.40+830.3%-71.6%$33.26M$145.24M-0.30380Upcoming EarningsGap DownSNYRSynergy CHC3.875 of 5 stars$3.50-3.0%$10.00+185.7%+3,260.0%$33.19M$33.59M0.0040Trending NewsJATTJATT AcquisitionN/A$1.91-2.6%N/A-62.8%$32.95MN/A0.003Gap DownHigh Trading VolumeKZRKezar Life Sciences3.6576 of 5 stars$4.30-1.1%$39.50+818.6%-36.1%$31.78M$7M-0.4060Negative NewsAnalyst DowngradeShort Interest ↑CLNNClene3.4968 of 5 stars$3.87+1.3%$40.00+933.6%-22.1%$31.58M$340K-0.96100Upcoming EarningsOKUROnKure Therapeutics2.5657 of 5 stars$2.32-0.4%$32.33+1,293.7%N/A$31.48MN/A-0.44N/ARNTXRein TherapeuticsN/A$1.44+1.4%N/AN/A$31.46MN/A-0.509Positive News Related Companies and Tools Related Companies ITRM Competitors AKTX Competitors MAAQ Competitors KPTI Competitors SNYR Competitors JATT Competitors KZR Competitors CLNN Competitors OKUR Competitors RNTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APRE) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aprea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aprea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
